PUBLISHER: Bizwit Research & Consulting LLP | PRODUCT CODE: 2004374
PUBLISHER: Bizwit Research & Consulting LLP | PRODUCT CODE: 2004374
Global GLP-1 Agonists Market Size Study and Forecast by Drug, Route of Administration, Age Group, Indication, Distribution Channel, and Regional Forecasts 2025-2035
Market Definition, Recent Developments & Industry Trends
The global GLP-1 agonists market comprises glucagon-like peptide-1 receptor agonist therapies used primarily for the management of type 2 diabetes and obesity. These drugs mimic the endogenous GLP-1 hormone, enhancing insulin secretion, suppressing glucagon release, delaying gastric emptying, and promoting satiety. The market includes branded and pipeline therapies delivered via injectable and oral routes, supported by pharmaceutical manufacturers, contract development and manufacturing organizations (CDMOs), distributors, healthcare providers, and payers.
Over the past decade, GLP-1 agonists have evolved from niche antidiabetic injectables to mainstream metabolic disease therapeutics with multi-indication potential. Recent clinical data demonstrating superior glycemic control, significant weight reduction, and cardiovascular benefits have accelerated adoption across both diabetes and obesity indications. Regulatory approvals for weight management, expansion into oral formulations, and increasing physician acceptance have transformed the competitive landscape. Looking ahead to 2035, continued innovation in long-acting formulations, combination therapies, and broader reimbursement coverage is expected to sustain double-digit growth and redefine the global metabolic therapeutics market.
Key Findings of the Report
- Market Size (2024): USD 53.79 billion
- Estimated Market Size (2035): USD 296.87 billion
- CAGR (2025-2035): 16.80%
- Leading Regional Market: North America
- Leading Segment: Semaglutide (Drug Segment)
Market Determinants
Rising Global Prevalence of Obesity and Type 2 Diabetes
The increasing burden of metabolic disorders is the primary structural driver of market expansion. Sedentary lifestyles, aging populations, and dietary shifts have led to a surge in diabetes and obesity cases globally. GLP-1 agonists offer clinically validated efficacy in both glycemic control and weight management, positioning them as cornerstone therapies in modern treatment protocols.
Clinical Superiority and Cardiometabolic Benefits
Beyond glucose regulation, GLP-1 agonists have demonstrated cardiovascular risk reduction and favorable metabolic outcomes. These additional benefits enhance their value proposition to physicians and payers, justifying premium pricing and supporting formulary inclusion across major healthcare systems.
Expansion into Obesity as a Standalone Indication
The transition from diabetes-focused therapy to obesity-centric treatment represents a significant commercial inflection point. With obesity increasingly recognized as a chronic disease requiring pharmacological intervention, demand has expanded beyond traditional endocrinology settings into primary care and weight management clinics.
Advancements in Drug Delivery and Oral Formulations
Innovation in oral GLP-1 formulations addresses historical barriers associated with injectable therapies, improving patient adherence and expanding the addressable population. Long-acting weekly and pipeline monthly formulations further enhance convenience and differentiation in a competitive market.
Pricing Pressures and Reimbursement Challenges
Despite strong demand, high therapy costs and limited reimbursement in certain markets may constrain adoption. Payer scrutiny over long-term cost-effectiveness, particularly for obesity treatment, could impact growth trajectories if access remains restricted in emerging economies.
Opportunity Mapping Based on Market Trends
Obesity Therapeutics Expansion
- Standalone obesity treatment programs
- Integration with digital weight management platforms
The formal recognition of obesity as a chronic condition creates a multi-billion-dollar expansion opportunity. Pharmaceutical companies that build integrated care ecosystems around GLP-1 therapies can capture recurring revenue streams and enhance patient retention.
Oral GLP-1 Penetration
- Improved patient adherence
- Broader primary care adoption
Oral formulations reduce injection-related barriers, opening the market to needle-averse populations and facilitating prescription growth in less specialized care settings.
Combination and Next-Generation Metabolic Therapies
- Dual or triple agonist pipelines
- Enhanced efficacy with reduced side effects
Emerging combination therapies targeting multiple metabolic pathways could redefine treatment standards and command premium pricing, representing a significant innovation-driven growth pocket.
Emerging Market Expansion
- Increasing diabetes awareness
- Gradual reimbursement improvements
As healthcare access expands in Asia Pacific and LAMEA, pharmaceutical manufacturers have opportunities to localize production and pricing strategies to unlock untapped patient pools.
Key Market Segments
By Drug:
- Semaglutide
- Exenatide
- Lixisenatide
- Liraglutide
- Dulaglutide
- Others
By Route of Administration:
- Oral
- Parenteral
By Age Group:
- Pediatric
- Adults
By Indication:
- Obesity
- Diabetes
- Others
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Value-Creating Segments and Growth Pockets
Semaglutide currently dominates the drug segment due to strong clinical performance, broad regulatory approvals, and expanding obesity indications. While established agents such as Liraglutide and Dulaglutide maintain significant market presence, next-generation molecules and combination therapies are expected to accelerate growth in the "Others" category over the forecast period.
Parenteral administration leads the market today given its long-standing clinical adoption. However, oral GLP-1 therapies are projected to witness faster growth, supported by improved patient convenience and expanding prescription volumes in primary care settings.
Adults represent the dominant age group due to higher prevalence rates of obesity and type 2 diabetes. Nevertheless, the pediatric segment may experience steady growth as clinical evidence and regulatory approvals expand for younger populations.
In terms of indication, diabetes remains foundational in revenue generation, while obesity is expected to outpace growth rates due to rising awareness, expanding approvals, and broader patient eligibility criteria.
Retail pharmacies currently account for a substantial share of distribution, though online pharmacies are poised for accelerated growth as digital health adoption and home-delivery models gain traction.
Regional Market Assessment
North America
North America leads the global market, driven by high obesity prevalence, advanced healthcare infrastructure, favorable reimbursement frameworks, and rapid uptake of innovative therapies. Strong marketing capabilities and early regulatory approvals further consolidate the region's leadership.
Europe
Europe demonstrates robust growth supported by rising obesity awareness and structured diabetes management programs. However, pricing negotiations and health technology assessments influence adoption rates across individual countries.
Asia Pacific
Asia Pacific is expected to register the fastest growth rate due to a rapidly expanding diabetic population, urbanization-driven lifestyle changes, and improving healthcare access. Strategic partnerships and localized manufacturing are key enablers in this region.
LAMEA
The LAMEA region shows emerging potential, particularly in the Middle East where obesity prevalence is high. While affordability and reimbursement remain constraints, gradual healthcare modernization supports long-term expansion opportunities.
Recent Developments
- March 2024: A leading pharmaceutical company expanded manufacturing capacity for semaglutide-based therapies to address global supply shortages, reinforcing competitive positioning amid surging demand.
- November 2023: Regulatory authorities approved expanded obesity indications for a GLP-1 therapy in key markets, broadening its commercial addressable population.
- June 2023: A biotechnology firm advanced a dual-agonist metabolic therapy into late-stage clinical trials, signaling intensifying competition and next-generation innovation within the segment.
Critical Business Questions Addressed
- How will the GLP-1 agonists market evolve in value terms through 2035?
The report analyzes revenue trajectories, growth drivers, and scenario-based forecasts across drugs and indications.
- Which drug classes and formulations offer the highest strategic returns?
Segment-level insights identify dominant products and emerging therapeutic innovations shaping future competition.
- How significant is the obesity indication in redefining market dynamics?
The study evaluates obesity-driven demand expansion and its impact on pricing, reimbursement, and distribution strategies.
- What regional markets should manufacturers prioritize for expansion?
Comparative regional analysis highlights regulatory, demographic, and reimbursement factors influencing growth.
- How will next-generation therapies alter competitive intensity?
The report assesses pipeline innovations and their implications for differentiation and market share redistribution.
Beyond the Forecast
GLP-1 agonists are transitioning from specialized metabolic treatments to central pillars of chronic disease management. The convergence of obesity recognition, cardiometabolic evidence, and formulation innovation will reshape therapeutic standards globally. Companies that integrate scalable manufacturing, lifecycle management, and multi-indication strategies will define leadership in the metabolic therapeutics ecosystem through 2035.
Table of Contents
Chapter 1. Global GLP-1 Agonists Market Report Scope & Methodology
- 1.1. Market Definition
- 1.2. Market Segmentation
- 1.3. Research Assumption
- 1.3.1. Inclusion & Exclusion
- 1.3.2. Limitations
- 1.4. Research Objective
- 1.5. Research Methodology
- 1.5.1. Forecast Model
- 1.5.2. Desk Research
- 1.5.3. Top Down and Bottom-Up Approach
- 1.6. Research Attributes
- 1.7. Years Considered for the Study
Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Strategic Insights
- 2.3. Top Findings
- 2.4. CEO/CXO Standpoint
- 2.5. ESG Analysis
Chapter 3. Global GLP-1 Agonists Market Forces Analysis
- 3.1. Market Forces Shaping The Global GLP-1 Agonists Market (2024-2035)
- 3.2. Drivers
- 3.2.1. Rising Global Prevalence of Obesity and Type 2 Diabetes
- 3.2.2. Clinical Superiority and Cardiometabolic Benefits
- 3.2.3. Expansion into Obesity as a Standalone Indication
- 3.2.4. Advancements in Drug Delivery and Oral Formulations
- 3.3. Restraints
- 3.3.1. Pricing Pressures and Reimbursement Challenges
- 3.4. Opportunities
- 3.4.1. Obesity Therapeutics Expansion
- 3.4.2. Oral GLP-1 Penetration
Chapter 4. Global GLP-1 Agonists Industry Analysis
- 4.1. Porter's 5 Forces Model
- 4.2. Porter's 5 Force Forecast Model (2024-2035)
- 4.3. PESTEL Analysis
- 4.4. Macroeconomic Industry Trends
- 4.4.1. Parent Market Trends
- 4.4.2. GDP Trends & Forecasts
- 4.5. Value Chain Analysis
- 4.6. Top Investment Trends & Forecasts
- 4.7. Top Winning Strategies (2025)
- 4.8. Market Share Analysis (2024-2025)
- 4.9. Pricing Analysis
- 4.10. Investment & Funding Scenario
- 4.11. Impact of Geopolitical & Trade Policy Volatility on the Market
Chapter 5. AI Adoption Trends and Market Influence
- 5.1. AI Readiness Index
- 5.2. Key Emerging Technologies
- 5.3. Patent Analysis
- 5.4. Top Case Studies
Chapter 6. Global GLP-1 Agonists Market Size & Forecasts by Drug 2025-2035
- 6.1. Market Overview
- 6.2. Global GLP-1 Agonists Market Performance - Potential Analysis (2025)
- 6.3. Semaglutide
- 6.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 6.3.2. Market size analysis, by region, 2025-2035
- 6.4. Exenatide
- 6.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 6.4.2. Market size analysis, by region, 2025-2035
- 6.5. Lixisenatide
- 6.5.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 6.5.2. Market size analysis, by region, 2025-2035
- 6.6. Liraglutide
- 6.6.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 6.6.2. Market size analysis, by region, 2025-2035
- 6.7. Dulaglutide
- 6.7.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 6.7.2. Market size analysis, by region, 2025-2035
- 6.8. Others
- 6.8.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 6.8.2. Market size analysis, by region, 2025-2035
Chapter 7. Global GLP-1 Agonists Market Size & Forecasts by Route of Administration 2025-2035
- 7.1. Market Overview
- 7.2. Global GLP-1 Agonists Market Performance - Potential Analysis (2025)
- 7.3. Oral
- 7.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 7.3.2. Market size analysis, by region, 2025-2035
- 7.4. Parental
- 7.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 7.4.2. Market size analysis, by region, 2025-2035
Chapter 8. Global GLP-1 Agonists Market Size & Forecasts by Age Group 2025-2035
- 8.1. Market Overview
- 8.2. Global GLP-1 Agonists Market Performance - Potential Analysis (2025)
- 8.3. Pediatric
- 8.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 8.3.2. Market size analysis, by region, 2025-2035
- 8.4. Adults
- 8.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 8.4.2. Market size analysis, by region, 2025-2035
Chapter 9. Global GLP-1 Agonists Market Size & Forecasts by Indication 2025-2035
- 9.1. Market Overview
- 9.2. Global GLP-1 Agonists Market Performance - Potential Analysis (2025)
- 9.3. Obesity
- 9.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 9.3.2. Market size analysis, by region, 2025-2035
- 9.4. Diabetes
- 9.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 9.4.2. Market size analysis, by region, 2025-2035
- 9.5. Others
- 9.5.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 9.5.2. Market size analysis, by region, 2025-2035
Chapter 10. Global GLP-1 Agonists Market Size & Forecasts by Distribution Channel 2025-2035
- 10.1. Market Overview
- 10.2. Global GLP-1 Agonists Market Performance - Potential Analysis (2025)
- 10.3. Hospital Pharmacies
- 10.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 10.3.2. Market size analysis, by region, 2025-2035
- 10.4. Retail Pharmacies
- 10.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 10.4.2. Market size analysis, by region, 2025-2035
- 10.5. Online Pharmacies
- 10.5.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 10.5.2. Market size analysis, by region, 2025-2035
Chapter 11. Global GLP-1 Agonists Market Size & Forecasts by Region 2025-2035
- 11.1. Growth GLP-1 Agonists Market, Regional Market Snapshot
- 11.2. Top Leading & Emerging Countries
- 11.3. North America GLP-1 Agonists Market
- 11.3.1. U.S. GLP-1 Agonists Market
- 11.3.1.1. Drug breakdown size & forecasts, 2025-2035
- 11.3.1.2. Route of Administration breakdown size & forecasts, 2025-2035
- 11.3.1.3. Age Group breakdown size & forecasts, 2025-2035
- 11.3.1.4. Indication breakdown size & forecasts, 2025-2035
- 11.3.1.5. Distribution Channel breakdown size & forecasts, 2025-2035
- 11.3.2. Canada GLP-1 Agonists Market
- 11.3.2.1. Drug breakdown size & forecasts, 2025-2035
- 11.3.2.2. Route of Administration breakdown size & forecasts, 2025-2035
- 11.3.2.3. Age Group breakdown size & forecasts, 2025-2035
- 11.3.2.4. Indication breakdown size & forecasts, 2025-2035
- 11.3.2.5. Distribution Channel breakdown size & forecasts, 2025-2035
- 11.3.1. U.S. GLP-1 Agonists Market
- 11.4. Europe GLP-1 Agonists Market
- 11.4.1. UK GLP-1 Agonists Market
- 11.4.1.1. Drug breakdown size & forecasts, 2025-2035
- 11.4.1.2. Route of Administration breakdown size & forecasts, 2025-2035
- 11.4.1.3. Age Group breakdown size & forecasts, 2025-2035
- 11.4.1.4. Indication breakdown size & forecasts, 2025-2035
- 11.4.1.5. Distribution Channel breakdown size & forecasts, 2025-2035
- 11.4.2. Germany GLP-1 Agonists Market
- 11.4.2.1. Drug breakdown size & forecasts, 2025-2035
- 11.4.2.2. Route of Administration breakdown size & forecasts, 2025-2035
- 11.4.2.3. Age Group breakdown size & forecasts, 2025-2035
- 11.4.2.4. Indication breakdown size & forecasts, 2025-2035
- 11.4.2.5. Distribution Channel breakdown size & forecasts, 2025-2035
- 11.4.3. France GLP-1 Agonists Market
- 11.4.3.1. Drug breakdown size & forecasts, 2025-2035
- 11.4.3.2. Route of Administration breakdown size & forecasts, 2025-2035
- 11.4.3.3. Age Group breakdown size & forecasts, 2025-2035
- 11.4.3.4. Indication breakdown size & forecasts, 2025-2035
- 11.4.3.5. Distribution Channel breakdown size & forecasts, 2025-2035
- 11.4.4. Spain GLP-1 Agonists Market
- 11.4.4.1. Drug breakdown size & forecasts, 2025-2035
- 11.4.4.2. Route of Administration breakdown size & forecasts, 2025-2035
- 11.4.4.3. Age Group breakdown size & forecasts, 2025-2035
- 11.4.4.4. Indication breakdown size & forecasts, 2025-2035
- 11.4.4.5. Distribution Channel breakdown size & forecasts, 2025-2035
- 11.4.5. Italy GLP-1 Agonists Market
- 11.4.5.1. Drug breakdown size & forecasts, 2025-2035
- 11.4.5.2. Route of Administration breakdown size & forecasts, 2025-2035
- 11.4.5.3. Age Group breakdown size & forecasts, 2025-2035
- 11.4.5.4. Indication breakdown size & forecasts, 2025-2035
- 11.4.5.5. Distribution Channel breakdown size & forecasts, 2025-2035
- 11.4.6. Rest of Europe GLP-1 Agonists Market
- 11.4.6.1. Drug breakdown size & forecasts, 2025-2035
- 11.4.6.2. Route of Administration breakdown size & forecasts, 2025-2035
- 11.4.6.3. Age Group breakdown size & forecasts, 2025-2035
- 11.4.6.4. Indication breakdown size & forecasts, 2025-2035
- 11.4.6.5. Distribution Channel breakdown size & forecasts, 2025-2035
- 11.4.1. UK GLP-1 Agonists Market
- 11.5. Asia Pacific GLP-1 Agonists Market
- 11.5.1. China GLP-1 Agonists Market
- 11.5.1.1. Drug breakdown size & forecasts, 2025-2035
- 11.5.1.2. Route of Administration breakdown size & forecasts, 2025-2035
- 11.5.1.3. Age Group breakdown size & forecasts, 2025-2035
- 11.5.1.4. Indication breakdown size & forecasts, 2025-2035
- 11.5.1.5. Distribution Channel breakdown size & forecasts, 2025-2035
- 11.5.2. India GLP-1 Agonists Market
- 11.5.2.1. Drug breakdown size & forecasts, 2025-2035
- 11.5.2.2. Route of Administration breakdown size & forecasts, 2025-2035
- 11.5.2.3. Age Group breakdown size & forecasts, 2025-2035
- 11.5.2.4. Indication breakdown size & forecasts, 2025-2035
- 11.5.2.5. Distribution Channel breakdown size & forecasts, 2025-2035
- 11.5.3. Japan GLP-1 Agonists Market
- 11.5.3.1. Drug breakdown size & forecasts, 2025-2035
- 11.5.3.2. Route of Administration breakdown size & forecasts, 2025-2035
- 11.5.3.3. Age Group breakdown size & forecasts, 2025-2035
- 11.5.3.4. Indication breakdown size & forecasts, 2025-2035
- 11.5.3.5. Distribution Channel breakdown size & forecasts, 2025-2035
- 11.5.4. Australia GLP-1 Agonists Market
- 11.5.4.1. Drug breakdown size & forecasts, 2025-2035
- 11.5.4.2. Route of Administration breakdown size & forecasts, 2025-2035
- 11.5.4.3. Age Group breakdown size & forecasts, 2025-2035
- 11.5.4.4. Indication breakdown size & forecasts, 2025-2035
- 11.5.4.5. Distribution Channel breakdown size & forecasts, 2025-2035
- 11.5.5. South Korea GLP-1 Agonists Market
- 11.5.5.1. Drug breakdown size & forecasts, 2025-2035
- 11.5.5.2. Route of Administration breakdown size & forecasts, 2025-2035
- 11.5.5.3. Age Group breakdown size & forecasts, 2025-2035
- 11.5.5.4. Indication breakdown size & forecasts, 2025-2035
- 11.5.5.5. Distribution Channel breakdown size & forecasts, 2025-2035
- 11.5.6. Rest of APAC GLP-1 Agonists Market
- 11.5.6.1. Drug breakdown size & forecasts, 2025-2035
- 11.5.6.2. Route of Administration breakdown size & forecasts, 2025-2035
- 11.5.6.3. Age Group breakdown size & forecasts, 2025-2035
- 11.5.6.4. Indication breakdown size & forecasts, 2025-2035
- 11.5.6.5. Distribution Channel breakdown size & forecasts, 2025-2035
- 11.5.1. China GLP-1 Agonists Market
- 11.6. Latin America GLP-1 Agonists Market
- 11.6.1. Brazil GLP-1 Agonists Market
- 11.6.1.1. Drug breakdown size & forecasts, 2025-2035
- 11.6.1.2. Route of Administration breakdown size & forecasts, 2025-2035
- 11.6.1.3. Age Group breakdown size & forecasts, 2025-2035
- 11.6.1.4. Indication breakdown size & forecasts, 2025-2035
- 11.6.1.5. Distribution Channel breakdown size & forecasts, 2025-2035
- 11.6.2. Mexico GLP-1 Agonists Market
- 11.6.2.1. Drug breakdown size & forecasts, 2025-2035
- 11.6.2.2. Route of Administration breakdown size & forecasts, 2025-2035
- 11.6.2.3. Age Group breakdown size & forecasts, 2025-2035
- 11.6.2.4. Indication breakdown size & forecasts, 2025-2035
- 11.6.2.5. Distribution Channel breakdown size & forecasts, 2025-2035
- 11.6.1. Brazil GLP-1 Agonists Market
- 11.7. Middle East and Africa GLP-1 Agonists Market
- 11.7.1. UAE GLP-1 Agonists Market
- 11.7.1.1. Drug breakdown size & forecasts, 2025-2035
- 11.7.1.2. Route of Administration breakdown size & forecasts, 2025-2035
- 11.7.1.3. Age Group breakdown size & forecasts, 2025-2035
- 11.7.1.4. Indication breakdown size & forecasts, 2025-2035
- 11.7.1.5. Distribution Channel breakdown size & forecasts, 2025-2035
- 11.7.2. Saudi Arabia (KSA) GLP-1 Agonists Market
- 11.7.2.1. Drug breakdown size & forecasts, 2025-2035
- 11.7.2.2. Route of Administration breakdown size & forecasts, 2025-2035
- 11.7.2.3. Age Group breakdown size & forecasts, 2025-2035
- 11.7.2.4. Indication breakdown size & forecasts, 2025-2035
- 11.7.2.5. Distribution Channel breakdown size & forecasts, 2025-2035
- 11.7.3. South Africa GLP-1 Agonists Market
- 11.7.3.1. Drug breakdown size & forecasts, 2025-2035
- 11.7.3.2. Route of Administration breakdown size & forecasts, 2025-2035
- 11.7.3.3. Age Group breakdown size & forecasts, 2025-2035
- 11.7.3.4. Indication breakdown size & forecasts, 2025-2035
- 11.7.3.5. Distribution Channel breakdown size & forecasts, 2025-2035
- 11.7.1. UAE GLP-1 Agonists Market
Chapter 12. Competitive Intelligence
- 12.1. Top Market Strategies
- 12.2. AstraZeneca
- 12.2.1. Company Overview
- 12.2.2. Key Executives
- 12.2.3. Company Snapshot
- 12.2.4. Financial Performance (Subject to Data Availability)
- 12.2.5. Product/Services Port
- 12.2.6. Recent Development
- 12.2.7. Market Strategies
- 12.2.8. SWOT Analysis
- 12.3. Biolingus
- 12.4. Boehringer Ingelheim
- 12.5. D&D Pharmatech
- 12.6. Eli Lilly
- 12.7. Gmax Biopharm
- 12.8. Hanmi Pharmaceutical
- 12.9. Innogen
- 12.10. Novo Nordisk
- 12.11. PegBio
- 12.12. Pfizer
- 12.13. QL Biopharma
- 12.14. Roche
- 12.15. Sanofi
- 12.16. Sciwind Biosciences
- 12.17. Tonghua Dongbao Pharmaceutical
- 12.18. Viking Therapeutics
